Particle.news
Download on the App Store
3 ARTICLES
·
10mo ago

Study Finds Low Risk of Secondary Cancers After CAR-T Cell Therapy

Research involving over 700 patients suggests CAR-T cell therapy is safer than previously thought, with secondary cancer risks comparable to other treatments.

Overview

  • FDA's 2023 warning about secondary cancers in CAR-T therapy prompted this study.
  • Stanford Medicine's research indicates a 6.5% risk of secondary cancers within three years.
  • The study found no evidence that engineered CAR-T cells caused secondary cancers.
  • Secondary cancers may arise due to pre-existing conditions or immunosuppression from treatment.
  • Findings emphasize the importance of monitoring and screening patients undergoing CAR-T therapy.